Garrett E Bergman

US Patent:

8101718, Jan 24, 2012

Filed:

Jul 1, 2009

Appl. No.:

12/496516

Inventors:

John S Lollar - Decatur GA, US
Garrett E. Bergman - Narberth PA, US

Assignee:

Emory University - Atlanta GA
Ipsen Biopharm Limited - Wrexham

International Classification:

A61K 38/00
A61K 38/37

US Classification:

530383, 530350, 514 2, 514 12, 424 91

Abstract:

The present invention provides a method of administering porcine B-domainless factor VIII (OBI-1) to a patient having factor VIII deficiency to provide more rapid and effective protection against bleeding episodes, compared to formerly available methods, or to provide more effective protection to such patients during non-bleeding periods. This invention is based on the discovery that the recombinant B-domainless porcine fVIII, termed OBI-1, has greater bioavailability compared to the natural porcine fVIII partially purified from porcine plasma, termed HYATE:C. Therefore, the inventive method employs lower unit doses of OBI-1, including, alternatively, omission of antibody-neutralizing dosage, or has longer intervals between the administration, compared to HYATE:C, to provide equivalent protection in patients having fVIII deficiency. The invention further provides pharmaceutical compositions and kits containing OBI-1 in combination with a pharmaceutically acceptable carrier, that are useful for treating patients in need of fVIII more effectively.

US Patent:

8501694, Aug 6, 2013

Filed:

Jan 23, 2012

Appl. No.:

13/356437

Inventors:

John S. Lollar - Decatur GA, US
Garrett E. Bergman - Narberth PA, US

Assignee:

Emory University - Atlanta GA
Baxter International Inc. - Deerfield IL
Baxter Healthcare SA - Glattpark (Opfikon)

International Classification:

A61K 38/37
A61P 7/04

US Classification:

514 141, 530383

Abstract:

The present invention provides a method of administering porcine B-domainless factor VIII (OBI-1) to a patient having factor VIII deficiency to provide more rapid and effective protection against bleeding episodes, compared to formerly available methods, or to provide more effective protection to such patients during non-bleeding periods. This invention is based on the discovery that the recombinant B-domainless porcine fVIII, termed OBI-1, has greater bioavailability compared to the natural porcine fVIII partially purified from porcine plasma, termed HYATE:C. Therefore, the inventive method employs lower unit doses of OBI-1, including, alternatively, omission of antibody-neutralizing dosage, or has longer intervals between the administration, compared to HYATE:C, to provide equivalent protection in patients having fVIII deficiency. The invention further provides pharmaceutical compositions and kits containing OBI-1 in combination with a pharmaceutically acceptable carrier, that are useful for treating patients in need of fVIII more effectively.

US Patent:

20070173446, Jul 26, 2007

Filed:

Oct 12, 2006

Appl. No.:

11/549049

Inventors:

John Lollar - Decatur GA, US
Garrett Bergman - Narberth PA, US

International Classification:

A61K 38/37

US Classification:

514012000

Abstract:

The present invention provides a method of administering porcine B-domainless factor VIII (OBI-1) to a patient having factor VIII deficiency to provide more rapid and effective protection against bleeding episodes, compared to formerly available methods, or to provide more effective protection to such patients during non-bleeding periods. This invention is based on the discovery that the recombinant B-domainless porcine fVIII, termed OBI-1, has greater bioavailability compared to the natural porcine fVIII partially purified from porcine plasma, termed HYATE:C. Therefore, the inventive method employs lower unit doses of OBI-1, including, alternatively, omission of antibody-neutralizing dosage, or has longer intervals between the administration, compared to HYATE:C, to provide equivalent protection in patients having fVIII deficiency. The invention further provides pharmaceutical compositions and kits containing OBI-1 in combination with a pharmaceutically acceptable carrier, that are useful for treating patients in need of fVIII more effectively.

US Patent:

20140193441, Jul 10, 2014

Filed:

Aug 5, 2013

Appl. No.:

13/959523

Inventors:

John S. Lollar - Decatur GA, US
Garrett E. Bergman - Narberth PA, US

International Classification:

A61K 39/00

US Classification:

4241851

Abstract:

The present invention provides a method of administering porcine B-domainless factor VIII (OBI-1) to a patient having factor VIII deficiency to provide more rapid and effective protection against bleeding episodes, compared to formerly available methods, or to provide more effective protection to such patients during non-bleeding periods. This invention is based on the discovery that the recombinant B-domainless porcine fVIII, termed OBI-1, has greater bioavailability compared to the natural porcine fVIII partially purified from porcine plasma, termed HYATE:C. Therefore, the inventive method employs lower unit doses of OBI-1, including, alternatively, omission of antibody-neutralizing dosage, or has longer intervals between the administration, compared to HYATE:C, to provide equivalent protection in patients having fVIII deficiency. The invention further provides pharmaceutical compositions and kits containing OBI-1 in combination with a pharmaceutically acceptable carrier, that are useful for treating patients in need of fVIII more effectively.